Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 235-241
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235
Table 2 Clinical outcomes
Response | n(%) |
PR | 4 (12.9) |
SD | 10 (32.3) |
Disease control (PR + SD) | 14 (45.2) |
Progressive disease | 17 (54.8) |
Survival outcome | median (range) |
Median TTP | 2.7 mo (1.0-14.8) |
Median OS | 7.8 mo (2.2-40.2) |
- Citation: Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
- URL: https://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.235